Saluda Medical

Saluda Medical is a neurotechnology company headquartered in Macquarie Park, Australia, operating at the forefront of the neuromodulation space. The company has developed the Evoke Spinal Cord Stimulation system, the world's first closed-loop SCS platform that continuously senses and responds to the spinal cord's evoked compound action potentials in real time. Unlike conventional open-loop systems that deliver fixed stimulation regardless of patient movement or position, Evoke automatically adjusts its output to maintain a consistent therapeutic effect. This closed-loop feedback mechanism represents a fundamental shift in how spinal cord stimulation therapy is delivered to patients living with chronic pain.

Saluda Medical has secured over $245 million in funding through a Series E round, reflecting strong investor confidence in both its technology and its commercial trajectory. The company has progressed through rigorous clinical evaluation, with its Evoke system supported by a growing body of evidence demonstrating superior consistency of stimulation delivery compared to traditional SCS approaches. These clinical milestones have positioned Saluda as a serious competitor to established players in the global neuromodulation market, which is valued at several billion dollars and continues to expand. The company's ability to attract significant capital underscores its readiness to scale commercially and pursue broader market access across key geographies.

Saluda Medical matters to the neurotech industry because it demonstrates that intelligent, adaptive systems can meaningfully improve patient outcomes in ways that legacy devices cannot. By introducing real-time physiological feedback into spinal cord stimulation, the company has set a new standard for what therapy-responsive neurotechnology can look like. This closed-loop paradigm has implications that extend well beyond chronic pain, offering a proof-of-concept model for adaptive neuromodulation across other indications and anatomical targets. As the broader neurotech field moves toward more personalized and responsive therapies, Saluda's work places it at the center of a defining technological transition in the industry.